Fobi Licenses its Wallet Pass Platform to CareSpace.AI for use in its CampusPass Vaccine Validation Platform for Higher Education Across North America
Memorandum of Understanding (MOU) calls for CareSpace to integrate Fobi’s real-time venue management solution across North American higher-level education facilities to provide secure vaccination validation and contactless capabilities
VANCOUVER, British Columbia, June 10, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI:TSX.V) (FOBIF:OTCQB) (the "Company" or "Fobi"), a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is pleased to announce the signing of a licensing agreement with CareSpace.AI. The deal will bring the use of the Fobi Wallet pass to higher education facilities throughout North America and provide secure covid-19 vaccination confirmation and validation, true contact-less registration, promotion, payment, and more using the Fobi Wallet pass technology, Fobi SmarTap, and Insight portal solutions for use in the CareSpace CampusPass platform (https://thecampuspass.com/). The CampusPass platform is being delivered in partnership with Microsoft and Unisys who are providing key elements of the data security and data privacy aspects of the platform.
LICENSING AGREEMENT WILL ENABLE FOBI TO EMPOWER COLLEGE CAMPUSES TO REOPEN AND RESUME ON-SITE ACTIVITIES AND EVENTS
With more than 100 college campuses across the US already stating they will require proof of vaccination to resume in-person classes and on-campus activities and many who have already implemented the policy, there is a monumental need for higher education facilities to have in place a platform to manage accurate and secure records, in order to limit liability and ensure the safety of students and staff. The integration of Fobi’s Wallet pass with the CampusPass platform will also offer community partners and sponsors increased ways to engage with students through personalized promotions, events, and digital touchpoints.
CareSpace is a strong strategic partner in the healthcare space, having had major success developing an emergency response platform for The International Red Cross, which is used by 96M+ volunteers worldwide. They are also the first Microsoft Health partner to drive dynamic patient education pathways via CRM connected platform for population health.
CareSpace CEO David Richards states:
“With higher-level institutions hit hard by the covid-19 pandemic, they are looking for new ways to entice students back to on-campus operations in a way that protects student identity and privacy, while opening new revenue opportunities. This agreement with Fobi will enable us to provide all of our campus clients with the ability to not only keep their students safe and secure but to enrich the student experience with new expanded touchless transaction opportunities. With the help of Fobi’s real-time capabilities, this platform will ensure that campuses see an increase in student and alumni loyalty and affinity with positive community impact at scale.”
Fobi CEO Rob Anson states:
“Both Fobi and CareSpace have seen great success within the venue management and events space over the past year, with CareSpace driving new population health programs through their HIPAA compliant platform and Fobi having had major success creating secure sporting events bubbles for the NCAA. We are confident that this agreement will enable us to continue to provide campuses across North America with the tools to resume operations and recoup lost revenue streams with our combined venue management tools.”
This agreement is expected to generate revenue for Fobi from an annual license and service agreement and Wallet pass fees. With over 3,982 degree-granting postsecondary institutions as of 2019-2020 and over 19 million students registered in the US alone, there is a significant potential market for Fobi Wallet passes.
Fobi provides significant value to the CareSpace platform and its campus clients due to our ability to integrate across all on-site locations and legacy infrastructure to provide real-time access to testing certification, contactless registration, a secure data portal, insights, and engagement. Together with CareSpace, we will provide higher education facilities and their community partners and sponsors with the tools to leverage real-time data to deliver an unparalleled next-generation on-campus experience.
CareSpace (www.carespace.ai) is a virtual assistant platform that utilizes artificial intelligence to help patients take an active role in their care beyond the walls of a hospital. Their platform delivers a scalable healthcare delivery model that’s patient-centered and remote provider-supported. CareSpace is core to digital health IT infrastructure and extends devices, telehealth, the EMR, and other digital health technologies to be more valuable to the patients, providers, insurance companies, and the employers they support.
CareSpace is a C-19 essential digital health company. CampusPass is built on the The Pass+ platform for population health and combines verifiable vaccine health credentials with world-leading security, privacy, and ethical standards.
CampusPass meets and exceeds the current standards and policies being implemented by state and local government.
As an end-to-end solution, (vaccine scheduling, admin, reporting, and sharing) CampusPass lowers population health risk; while powering the new connected smart campus.
Fobi is a cutting-edge data intelligence company that helps our clients turn real-time data into actionable insights and personalized customer engagement to generate increased profits. Fobi’s unique IoT device has the ability to integrate seamlessly into existing infrastructure to enable data connectivity across online and on-premise platforms creating highly scalable solutions for our global clients. Fobi partners with some of the largest companies in the world to deliver best-in-class solutions and operates globally in the retail, telecom, sports & entertainment, casino gaming, and hospitality & tourism industries.
For more information, please contact:
|Fobi AI Inc.||CareSpace, Inc.||Fobi Website: www.fobi.ai|
|Rob Anson, CEO||David Richards, CEO||Facebook: @ Fobiinc|
|T : +1 877-754-5336 Ext. 4||T: 503.290.4943||Twitter: @ Fobi_inc|
|E: firstname.lastname@example.orgemail@example.com||LinkedIn: @ Fobiinc|
This news release contains certain statements that constitute forward-looking statements or information, including statements regarding Fobi's business and technology; the ability of Fobi to engage with industry participants to achieve its goals; the development of Fobi's technology; and the viability of Fobi's business model. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Fobi's control, including the impact of general economic conditions, industry conditions, competition from other industry participants, stock market volatility, and the ability to access sufficient capital from internal and external sources. Although Fobi believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated, or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity, or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Fobi does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Fobi should be considered highly speculative. There can be no assurance that Fobi will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Supersapiens Powered by Abbott’s Libre Sense Glucose Sport Biosensor Announces Garmin Integration22.6.2021 16:30:00 CEST | Press release
New Connect IQ app gives athletes timely glucose levels on their bike computer and wrist, allowing for real-time adjustments to sustain peak performance Atlanta, GA, USA, June 22, 2021 (GLOBE NEWSWIRE) -- Supersapiens, powered by Abbott’s Libre Sense Glucose Sport Biosensor, is announcing its initial integration of the Supersapiens Connect IQ app with Garmin®. The Supersapiens training ecosystem empowers athletes to optimize fueling, maximize training, and increase performance gains. The integration will provide select users with a compatible Garmin smartwatch or Edge® cycling computer with real-time glucose visibility allowing them to go faster longer. The Supersapiens app can be downloaded now from the Connect IQ™ store. A partnership with global healthcare leader Abbott makes Supersapiens the only energy management ecosystem that directly integrates with a Bluetooth-enabled sports continuous glucose monitor (CGM) — the Abbott Libre Sense Glucose Sport Biosensor. Supersapiens offers
Painter 2022: Must-Have Upgrade for Professional Artists Delivers a Faster, More Powerful Digital Painting Experience22.6.2021 15:01:00 CEST | Press release
Offering unprecedented performance, a streamlined workflow, and improved layer productivity, Painter 2022 makes it easier than ever for artists to create exceptional work OTTAWA, June 22, 2021 (GLOBE NEWSWIRE) -- Painter 2022 responds to users’ top requests and delivers a must-have upgrade by expanding creative possibilities. Designed for Windows 10 and macOS, this powerful and creative digital painting software adds enhancements that focus on accelerating workflows, boosting brush performance, and improving layer productivity to offer a game-changing digital art studio for today’s professional and aspiring artists. “We know the critical role Painter plays in professional artists’ workflows and are honored to be part of the creative process of bringing some of pop culture's most iconic movies, characters and games to life,” said Chris Pierce, Director of Product for Photo and Digital Arts at Corel. “With this version we focused on our customers’ top requests and whether it’s improvemen
IMCD N.V. shareholders adopt all resolutions at AGM22.6.2021 13:55:00 CEST | Press release
ROTTERDAM, The Netherlands (22 June 2021) – IMCD N.V. (hereafter “IMCD” or the “Company”) announces that all resolutions proposed to the shareholders at the Company’s Annual General Meeting (“AGM”) held today were adopted. This includes the adoption of the financial statements for the year 2020 and approval of the dividend proposal of EUR 1.02 per share in cash. The dividend calendar is as follows: Thursday 24 June 2021 - Ex-dividend date Friday 25 June 2021 - Record date Monday 28 June 2021 - Payment date Further resolutions included the reappointment of Deloitte Accountants B.V. as external auditor for the year 2021. The 2020 Remuneration Report received a positive advisory vote with over 94% of voted casted in favor of the report. Details of the Annual General Meeting, including the voting results, are available at IMCD’s corporate website. Attached, please find the press release in pdf format. Attachment PR_IMCD 2021 AGM resolutions
About making of a mandatory share buy-back offer22.6.2021 13:25:00 CEST | Press release
Joint stock company “Olainfarm”, hereinafter referred to as - “the Company”, hereby informs that on the 22nd of June, 2021 Joint stock company “AS “AB CITY””, registration number 40203174414, according to the clause 1 of the article 73 of the Financial Instrument Market Law, informed the Board of the Company about making of a mandatory share buy-back offer. The Board of the joint stock company “Olainfarm” will prepare conclusion and announce its opinion about the offer within terms set by the Financial Instrument Market Law after an advertisement regarding making of a share buy-back offer is published. Additional information: Jānis Dubrovskis Investor Relations Advisor of JSC Olainfarm Phone: +371 29178878 Email: firstname.lastname@example.org
Verisk’s AIR Updates Its Terrorism Model to More Comprehensively Model Damage from Conventional Bomb Blast Attacks22.6.2021 12:11:00 CEST | Press release
BOSTON, June 22, 2021 (GLOBE NEWSWIRE) -- Catastrophe modeling firm AIR Worldwide announced that it has updated its Terrorism Model for the United States to more comprehensively model the extent of damage from conventional bomb blast attacks. Starting with the size and location of the bomb, the model propagates the appropriate blast intensity within a built environment from the exterior to the interior of buildings to yield damage and loss estimates, including property damage and workers’ compensation, and personal injury. AIR Worldwide is a Verisk (Nasdaq:VRSK) business. “When terrorists use conventional weapons—the effects of which tend to be highly localized—they are likely to be targeting specific buildings or facilities,” said Tao Lai, vice president, research, AIR Worldwide. “The amount of damage that occurs at or near the site of an attack depends on a wide variety of factors. In addition to the type of weapon used, the surrounding buildings, building dimensions and blast intens
RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS22.6.2021 11:07:00 CEST | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2021-06-22Loan2311 Coupon1.00 %ISIN-codeSE0010948240Maturity2023-11-13 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln2,020Volume bought, SEK mln500Number of bids6Number of accepted bids2Average yield0.034 %Lowest accepted yield0.033 %Highest yield0.034 %% accepted at lowest yield 56.82 Auction date2021-06-22 Loan2505 Coupon1.00 %ISIN-codeSE0011414010Maturity2025-05-12 Tendered volume, SEK mln1,000 +/- 500 Volume offered, SEK mln3,000Volume bought, SEK mln1,000Number of bids8Number of accepted bids1Average yield0.219 %Lowest accepted yield0.219 %Highest yield0.219 %% accepted at lowest yield 100.00 Auction date2021-06-22 Loan2805 Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln750 +/- 350 Volume offered, SEK mln1,000Volume bought, SEK mln750Number of bids3Number of accepted bids1Average yield0.623 %Lowest accepted yield0.623 %Highest yield0.623 %% accepted at lowest yield 100.00
RESULT OF RIKSBANK CERTIFICATE SALE22.6.2021 10:15:00 CEST | Press release
AuctionAuction resultsAuction date2021-06-22Start date2021-06-23Maturity date2021-06-30Interest rate, %0.00Offered volume, SEK bn490.0Total bid amount, SEK bn2263.5Accepted volume, SEK bn490.0Number of bids16Percentage alloted, %21.648